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Imaging Beta-Adrenoceptors in the Human Brain
with (5)-l'-[18F]Fluorocarazolol
Aren van Waarde, Ton J. Visser, Philip H. Elsinga, Bauke M. de Jong, Thorn W. van der Mark, Jan Kraan, Kees Ensing,
Jan Pruim, Antoon T.M. Willemsen, Otto-Erich Brodde, Gerben M. Visser, Anne M.J. Paans and Willem Vaalburg
PET Center, Department of Neurology and Department of Pulmonary Diseases, University Hospital and Department of
Analytical Chemistry and Toxicology, University Center for Pharmacy, Groningen, The Netherlands; Institute of
Pharmacology and Toxicology, Martin Luther University, Halle/Saale, Germany
We evaluated the suitability of fluorocarazolol for in vivo studies of
cerebral beta-adrenoceptors because (S)-1'-[18F]fluorocarazolol has
a higher affinity to beta-adrenoceptors than to serotonergic recep
tors (pK, p, 9.4, ÃŸ210.0, 5HT1A 7.4, 5HT1B 8.1) and rapidly crosses
the blood-brain barrier. Methods: The (S)-[18F]fluorocarazolol (74
MBq, >37 TBq/mmol) was intravenously administered to healthy
volunteers on two separate occasions with an interval of at least 1
wk. The initial injection was without pretreatment, but before the
second injection, the volunteers received the beta blocker (Â±)-
pindolol (3x5 mg orally, during 18 hr). The brain was studied with
a PET camera in dynamic mode. Results: Uptake of radioactivity
delineated gray matter and was particularly high in the posterior
cingulate, precuneus and striatum. Low uptake occurred in the
thalamus, whereas the lowest uptake was observed in the white
matter of the corpus callosum. After pindolol pretreatment, uptake
was reduced and its distribution became homogeneous throughout
the brain. The ratio of total-to-nonspecific binding was about 2 at 60
min, increasing to 2.5-2.75 at longer intervals. Conclusion: Fluoro
carazolol is the first radioligand that can visualize cerebral beta-
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r\.n intriguing problem in biomedicai research is that of
relating symptoms of neurological as well as psychiatric distur-
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bances to altered neurotransmitter binding in distinct regions of
the brain. Cerebral beta-adrenergic binding sites for the neuro
transmitter noradrenaline have been reported to be affected in a
variety of disorders, such as depression (7,2), schizophrenia (3),
alcoholism (4), Alzheimer's disease (5) and Huntington's cho
rea (fi). They appear to play a role in many physiological and
behavioral responses, such as glial proliferation (7,8), control of
respiration (9), processing of visual information (10), memory
function (77) and adaptation to stress (72). The generally
observed delayed onset of action of antidepressant drugs may
occur because downregulation of beta-adrenoceptors and sero
tonergic receptors takes place only after chronic drug adminis
tration (13,14). Receptor downregulation could be a prerequi
site of the antidepressant activity (75). Receptor density may
also change when noradrenergic innervation is impaired. Dete
rioration of noradrenergic neurons occurs such as in the
Parkinson dementia complex (16).
Most of these observations have been made in autopsy
studies, in binding assays to human lymphocytes and cultured
cells or in animal experiments. None of these relationships has
been observed in intact humans by external detection with
receptor-specific radioligands. Fluorocarazolol, a fluorinated
analog of the potent beta-blocker carazolol has been useful in in
vivo studies of beta-adrenoceptors, both in experimental ani
mals (77-79) and in humans (20). Uptake in the rat brain is
saturable, sensitive to selective beta-adrenoceptor antagonists
and stereospecific. We now report the first results obtained with(S)-l'-[18F]fluorocarazolol-PET to visualize the distribution of
beta-adrenoceptors in the brain of healthy volunteers.
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MATERIALS AND METHODS
Radioligand
(SVDesisopropylcarazolol (enantiomeric excess >98%) was
prepared as reported previously (17). (S)-l'-[18F]fluorocarazolol
was synthesized by reacting the precursor with [18F]fluoroacetone
(17,19) and purified by HPLC. The specific activity was 75 Â±35
TBq/mmol (2040 Â±950 Ci/mmol) and the radiochemical purity
was >99.8%. The ligand was dissolved in 0.5 ml ethanol/pro-
pylene glycol/0.9% NaCl (1/2/2 v/v/v). Before injection, this
solution was filtered (0.22 /urn) and 7.5 ml 0.9% NaCl were added
through the filter. The solution was sterile and apyrogenic. (5)-1 '-
fluorocarazolol. HC1 passed the test on acute toxicity (European
Pharmacopeia; Dutch Pharmacopeia Ed. IX) at a 10,000-fold
higher dose than was administered to humans.
In Vitro Binding Assays
The affinity of (5)â€”1'-fluorocarazolol to ÃŸ,-and ÃŸ2-adrenocep-
tors was assessed in membranes prepared from human right atrial
tissue and human lymphocytes, respectively, using (-)-[125I]iodo-
cyanopindolol as the radioligand (21). Affinity of (S)â€”1'-fluoro
carazolol to 5HT,A receptors was determined in bovine hippocam-
pal membranes using 1.0 nM [3H]-8-OH-DPAT as the
radioligand; the affinity to 5HT,B receptors was measured in rat
striatal membranes, using 150 pM [125I]iodocyanopindolol in the
presence of 60 ju.A/(-)- isoproterenol. The resulting IC50 values
were converted to KÂ¡values according to the Cheng and Prusoff
equation (22): KÂ¡= IC50/([S]/Kd + 1), where IC50 = concentration
of fluorocarazolol that inhibited radioligand binding by 50%, [S] =
concentration of radioligand in the assay and Kd = equilibrium
dissociation constant of the radioligand. The ÃŸ,-and ÃŸ2-adreno-
ceptor assays were performed by the Institut fÃ¼rPharmakologie
und Toxikologie, Halle, Germany; affinities to 5HT,A and 5HT,B
receptors were determined by NovaScreen (Hanover, MD).
Human Volunteers
Healthy volunteers were recruited through advertisements in a
local newspaper. Excluded were people with; (a) a positive history
regarding neuropsychiatrie disease; (b) use of antidepressants,
beta-blockers, beta-mimetics or theophylline; (c) high blood pres
sure or heart failure; or (d) pregnancy or suspected pregnancy. All
volunteers had the following screening: medical history, physical
examination, routine blood biochemistry to assess kidney and liver
function, and electrocardiogram. The study was approved by the
Medical Ethics Committee of the Groningen University Hospital.
Each subject was informed about the purpose and hazards of the
experiment both orally and in writing and gave informed consent.
Study Protocol
At the beginning of the study, a cannula was placed in a vein of
one of the lower forearms. Another cannula was placed in a radial
artery of the contralateral arm after patency of the ulnar artery had
been proven by the Allen test. The arterial cannula was inserted
under local anesthesia with lidocain. The venous cannula was used
for injection of the ligand, the arterial line for blood sampling.
The volunteer was then placed on the PET camera (Siemens
ECAT 951/31, Knoxville, TN, FWHM = 6 mm, axial field of view
10.8 cm, images reconstructed in 31 planes). Volunteers were
positioned to the orbito-meatal line. Next, a transmission scan was
produced using the internal 68Ge/68Ga sources to correct for
attenuation. Cerebral blood flow was assessed by bolus injection of
1.85 GBq (50 mCi) H2I5O (using a Medrad OP-100 remote-
controlled pump, total volume 40 ml at a speed of 8 ml/sec"1) to
make sure that no perfusion defects were present. Data acquisition
was started at the onset of injection: four frames of 5 sec were
followed by one frame of 10 sec, two frames of 30 sec and one
frame of 2 min. Total duration of the study was 3.5 min. After an
interval of at least 10 min (i.e., 5 half-lives of 15O), (5)-!'-
[18F]fluorocarazolol (on average 63 MBq = 1.7 mCi) was injected
over a period of 1 min, using the Medrad pump.
Data acquisition was started at the onset of injection: eight
frames of 15 sec were followed by four frames of 30 sec, four
frames of 1 min, four frames of 2 min, six frames of 4 min and two
frames of 10 min. Total duration of the study was 60 min. Arterial
blood samples (2 ml) were drawn at 0.5-min intervals during the
initial 5 min and at 10-min intervals from 10 to 60 min postinjec
tion. Radioactivity in plasma and in a cell pellet (5 min 3000 g) was
determined in all samples using a gamma counter that was
cross-calibrated with the PET camera. Additional samples (3 ml)
drawn at 1,2, 5, 10, 20, 40 and 60 min were used for metabolite
analysis. Plasma was analyzed for the presence of (S)â€”1'-
[18F]fluorocarazolol and radioactive metabolites by direct injection
onto an internal-surface reversed-phase column 150 X 4.6 mm;
mobile phase 10 mM K2HPO4:acetonitrile 90:10, pH 7.5; flow rate1.5 ml.min~') as published previously (23).
After an interval of at least 1 wk, the volunteer returned for the
second part of the study in which the influence of a beta-
adrenoceptor antagonist on tissue uptake of (S)â€”l'-[l8F]fluoro-
carazolol was assessed. Each volunteer took pindolol orally: 5 mg
on the evening before the experiment, 5 mg on the morning before
the experiment and 5 mg 60 min before injection of the radioligand.
Cannulas were placed in a vein of each of the lower forearms.
No arterial catheter was used in the second part of the study to keep
inconvenience to the volunteer to a minimum. One cannula was
used for injection and the other for blood sampling. Tracer
injection, data acquisition and sampling were performed as on day
one.
Data Analysis
ROIs were drawn by hand on white matter (corpus callosum),
posterior part of the gyrus cinguli including precuneus, striatum,
thalamus and cerebral cortex (comprising both hemispheres in a
section just superior to the border of white and gray matter).
Time-activity curves for the ROIs were calculated using ECAT
software (version 6.5D) running on a Sun/Spare (Mountain View,
CA) workstation. All data were normalized to an injected radioac
tivity of 74 MBq (2 mCi) and a body weight of 70 kg. The
time-activity data were exported to an IBM-compatible PC and
characterized using a nonlinear regression data analysis program
(EnzFitter, Elsevier Biosoft, Cambridge, U.K.). Differences be
tween groups were tested using one-way analysis of variance and
appropriate software (Statistix, NH Analytical, Roseville, MN). A




Preliminary in vitro assays showed that (S)â€”!'-fluorocara
zolol binds preferentially to beta-adrenoceptors (pKÂ¡at the
/3,-subtype: 9.4, at the /32-subtype: 10.0) and has less affinity to
5HT1A (pKÂ¡7.4) and 5HTm (pKÂ¡8.1) serotonergic sites. These
results encouraged us to initiate the pilot study in healthy
volunteers.
Details regarding the participants and the study protocol are
presented in Table 1. None of the volunteers showed any
symptoms of heart failure, hypertension or neuropsychiatrie
disease.
Distribution of Radioactivity within the Brain
The cerebral distribution of the flow tracer, H2'5O, delineated
gray matter as expected. Representative images acquired after
injection of S-l'-['8F]fIuorocarazolol are presented in Figure 1.
Transaxial cross-sections in the time frame 14-60 min are
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TABLE 1
Volunteers and Study Protocol
Injected
Volunteer Age Weight Pre- mass
Date no. (yr) Sex (kg) treatment (nmol) Scan type
05-24-9505-31-9507-12-9507-19-9508-02-9509-20-9511-01-9511-08-9511-29-9512-13-9501-03-9601-17-9602-28-9602-14-96Mean
Â±s.d.11223344566778365527212822212529Â±11(8)MMFMMFMM678256727670697070Â±7(8)NonePindololNonePindololNonePindololNonePindololNoneNonePindololNonePindololNone0.881.010.680.671.750.590.400.351.331.570.670.240.710.270.79Â±0.47(14)StaticStaticDynamicDynamicStaticStaticDynamicDynamicStaticDy amicDynamicDynamicDynamicDynamic
displayed. In the initial study (without pindolol), gray matter
was clearly demarcated from white matter. Uptake of radioac
tivity was especially high in the cortical areas (posterior
cingulate, precuneus) and the corpus striatum (caudate and
putamen, Fig. 1). Low uptake occurred in the thalamus. The
lowest uptake was observed in the white matter (corpus callo-
sum, see Fig. 1). This relatively high striata! uptake and low
uptake in the thalamus contrasted with the more even distribu
tion of radioactivity seen in the H215Oscans. In one volunteer,
a hot spot was visible just ventrally to the cerebellum and
interpreted as the putative locus coeruleus (see Fig. 1). After
ingestion of pindolol, cerebral uptake of radioactivity was
strongly (>two-fold) suppressed and gray matter was no longer
demarcated, as the distribution of radioactivity became virtually
homogeneous throughout the brain (see Fig. 1 and Table 2). The
hot spot near the cerebellum also disappeared after preloading
of the volunteer with pindolol.
Kinetics of Cerebral (S)-1 '-[18F]Fluorocarazolol Uptake
After injection of the radioligand, cortical levels of radioac
tivity rapidly rose to a maximum followed by an equally rapid,
small decline to a relatively stable plateau that was reached
within 3 min (Fig. 2). Pindolol accelerated the washout of
radioactivity from the cortex (Fig. 2) and it reduced cortical
radioactivity to <50% of the control at 60 min postinjection. In
contrast to the data for cerebral cortex, uptake of radioactivity
in the white matter of the corpus callosum was not significantly
affected by pindolol (Fig. 2). Uptake in the corpus callosum was
about equal to that in the cortex of pindolol-treated subjects
at >30 min posti jecti n (Fig. 2).
If uptake of radioactivity in the presence of pindolol is
considered to represent nonspecific binding, ratios of total-to-
nonspecific binding can be calculated. In the cerebral cortex,
this parameter increased during the whole period of PET
scanning, and it was not yet maximal after 60 min (Fig. 3). The
curve fitted to the data suggests that a maximum of 2.52 is
reached with a first-order rate constant of 0.0222 min"1 (i.e.,
time required to reach 50% of the maximum = 31 min).
Washout of radioactivity from the brain of untreated subjects
is slow and it appears to be different in different brain areas
(faster in thalamus than in other areas of the brain). The relative
amount of radioactivity which remains in different areas at 60




FIGURE 1. PET brain images at the level of the cingulate cortex + precuneus, striatum and locus coeruleus (from left to right).The upper row of images was
acquired in the untreated condition; the lower row after the volunteer had ingested pindolol (time frame 14-60 min). The volunteer is on his back; the direction
of observation is from his feet towards his head.
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TABLE 2

















"Significant differences between the untreated and pindolol-preloaded
condition (one-way ANOVA P < 0.05).
Tissue uptake of radioactivity is expressed as camera units (ECAT
cts/pixel/sec) x 104. Data are an average Â±s.e.m. of all dynamic studies (five
in the control condition, four after pindolol preload); values were normalized
to an injected dose of 74 MBq (2 mCi).
min is: cingulate cortex plus precuneus = striatum > other
parts of the cortex > thalamus > white matter of the corpus
callosum.
Effect of Beta-Blockade on Radioligand Clearance and
Metabolism
Preloading of volunteers with pindolol affects clearance and
metabolism of the radioligand (Fig. 4). Levels of radioactivity
in the circulation at 20-60 min postinjection are higher, and the
fraction of plasma radioactivity representing parent compound
also is higher after treatment of volunteers with pindolol.
Similar results had been obtained in a previous study of
beta-adrenoceptors in the human thorax (20).
DISCUSSION
Selectivity of Fluorocarazolol
Many beta-blockers interact with central serotonergic sites
(24-26). lodocyanopindolol (24,26), pindolol (27), carteolol
(25) and propranolol (25,27) bind almost equally well to 5HT]A
and/or 5HT1B receptors as to beta-adrenoceptors. In contrast,
hydrophilic atenolol (25) and CGP-12177 (26) are selective
beta-adrenoceptor antagonists. Unfortunately, uC-atenolol and
"C-CGP 12177 cannot be used for PET studies of the brain as
CGP 12177 hardly crosses the blood-brain barrier (28,29),
while the affinity of atenolol is too low for succesftil beta-
adrenoceptor imaging (30). Because of its lipophilicity [log P
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FIGURE 3. Ratios of total/nonspecific binding in cerebral cortex, calculatedfrom tissue uptake of (S)-1'-[18F]fluorocarazolol in the presence and absence
of pindolol (mean Â±s.e. of four volunteers).
transport over the blood-brain barrier. Indeed, we have ob
served that (S)-l'-[l8F]fluorocarazolol enters rat brain and it
demonstrates significant specific binding in cerebral cortex and
cerebellum (Â¡8).In vitro binding assays have shown a much
higher affinity of fluorocarazolol to beta-adrenoceptors than to
5HT1Aor 5HT1Breceptors (see Results). The 20- to 400-fold
selectivity of fluorocarazolol for beta-adrenoceptors indicates
that serotonergic sites will not significantly contribute to the
specific binding in the brain after administration of a nanomolar
dose of the radioligand (see also below).
Distribution of Binding Sites for Fluorocarazolol within
the Brain
Whether a ligand binds to receptors in the living human brain
can be determined by assessing whether the regional distribu
tion of radioactivity after drug injection parallels the distribu
tion of receptors known from post mortem autoradiography,
and by examining whether administration of an excess of an
RGURE 2. Time-activity curves in two
areas of the human brain after injection of(S)-V-[18F]fluorocarazolol. Data are an
average of all dynamic studies (five in the
untreated condition, four after ingestion
of pindolol; values were normalized to an
injected dose of 74 MBq [2 mCi]). Tissue
uptake of radioactivity is expressed as
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FIGURE 4. Clearance of 18Ffrom human
plasma after injection of (S)-1'-[18F]fluoro-
carazolol, and the fraction of plasma ra
dioactivity representing metabolites. Data
are an average of all dynamic studies (five
in the untreated condition, four after in
gestion of pindolol; values were normal
ized to an injected dose of 74 MBq [2
mCi]).
unlabeled receptor antagonist blocks this specific regional
distribution. Both approaches were used in this study.After administration of (5)-l'-[18F]fluorocarazolol to volun
teers, distribution of radioactivity within the brain was inhomo-
geneous. Relatively high uptake was observed in the striatum
and cortical areas (especially cingulate cortex and precuneus).
Low levels of radioactivity were present in the thalamus and the
lowest in white matter. Such a distribution corresponds to the
localization of /3-adrenoceptors known from post mortem au-
toradiography with the ligands [I25l]iodocyanopindolol,
[I25l]iodopindolol and [3H]CGP 12177: high beta-adrenoceptor
densities are found in caudate and putamen (2,13,31-33),
moderate to high densities in various cortical areas (2,13,31-33)
and low densities in thalamus (2,13,32) and white matter
(33,34). With the most selective beta-adrenoceptor ligand,
[3H]CGP-12177, the following receptor densities were mea
sured: caudate/putamen 100-134, cortex 55-80, thalamus
38-45 and white matter <20 fmol/mg protein (1,2,13,31). If
we assume that 10% of tissue wet weight consists of protein,
receptor densities in cortex range from 5.5-8.0 pmol/g. The
cerebral concentration of fluorocarazolol in this study was <
0.03 pmol/ml. Thus, beta-adrenoceptor occupancy by fluoro
carazolol was negligible (i.e., <0.5%).
In one volunteer (Volunteer 2), the putative locus coeruleus
was delineated after injection of (S)-l'-[18F]fluorocarazolol.
The locus coeruleus does not contain a particularly high amount
of beta-adrenoceptors, but strong nonspecific binding of
[I25l]iodocyanopindolol has been reported in this region, which
is probably related to the presence of neuromelanin (32). The
observation that a pindolol preload suppresses uptake of 18Fin
the pons of Volunteer 2 (Fig. 1) suggests that binding of
fluorocarazolol, in contrast to that of iodocyanopindolol, is not
truly nonspecific but takes place to non-beta-adrenergic sites as
has been reported for iodocyanopindolol in the heart (35).
Blockage of the Specific Regional Distribution by an
Unlabeled Beta-Adrenoceptor Antagonist
Pindolol is a nonsubtype-selective beta-adrenoceptor antag
onist with substantial affinity to 5HT,A receptors (27). Other
beta-blockers that penetrate the brain and are registered as
drugs, such as propranolol, bind even to 5HT1A-and 5HT1B-
sites (25). We selected pindolol for our blocking experiments
because the drug has intrinsic sympathomimetic activity; un-
desired side effects on heart rate and sleep are less frequent after
ingestion of pindolol than of propranolol.Pindolol induced a more rapid washout of (5)-l'-[18F]fluo-
rocarazolol-derived radioactivity from receptor-containing ar
eas of the brain but not from areas with very low receptor
density such as the white matter of the corpus callosum (Fig. 2).
Local differences in tissue uptake of radioactivity within the
brain observed 14-60 min after injection of the radioligand
were absent when the volunteers had ingested pindolol (Fig. 1).
Uptake in all regions then became similar to that in the corpus
callosum. Thus, administration of an excess of an unlabeled
receptor antagonist blocked the specific regional distribution of(5)-l'-[18F]fluorocarazolol within the brain.
CONCLUSION(5)-l'-[18F]fluorocarazolol, a potent beta-adrenergic receptor
antagonist, specifically accumulated in gray matter after in vivo
administration to humans. Uptake is particularly high in the
striatum and in various cortical areas, regions with a high
density of beta-adrenoceptors. Preferential localization in stri
atum and cortex is blocked by administration of an excess of an
unlabeled beta-adrenoceptor antagonist (pindolol). These data,
combined with results from animal experiments, indicate that
the distribution of radioactivity reflects radioligand binding to
beta-adrenoceptors. White matter of the corpus callosum can
probably be used as a reference region to estimate nonspecific
binding. It may now be feasible to assess the role of human
cerebral beta-adrenoceptors in the action of antidepressant
drugs and in disorders such as depression and schizophrenia.
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Cerebral Sparganosis: Increased Uptake of
Technetium-99m-HMPAO
Dong-Ling You, Kai-Yuan Tzen, Pan-Fu Kao, Yat-Sen Ho and Chun-Che Chu
Departments of Nuclear Medicine, Pathology and Neurology, Chang Gung Memorial Hospital, Taipei, Taiwan
Cerebral sparganosis is an extremely rare Â¡ntracranialparasitic
infectious disease. We report findings of ""Tc-HMPAO cerebral
perfusion SPECT in a case with cerebral sparganosis. SPECT
revealed an irregularly shaped area with markedly increased 99mTc-
HMPAO uptake in the parasitic infectious region of the cerebrum.
Both white and gray matter was involved, the white matter involved
predominantly. Decreased perfusion to the right cerebellum, sug
gesting cross cerebellar diaschisis, was also demonstrated. This
article illustrates that cerebral sparganosis is one of the causes of
increased 99nTc-HMPAO uptake in the cerebrum and should be
considered clinically if present.
Key Words: sparganosis; technetium-99m-HMPAO; cerebral per
fusion SPECT
J NucÃ-Med 1997; 38:939-941
\_/erebral sparganosis is an extremely rare central nervous
system (CNS) parasitic infectious disease caused by the plero-
cercoid larva, called sparganum, of Spirometra mansonoides
(1,2). Most cases of cerebral sparganosis have been reported
from Korea, Japan, China, Taiwan and Southeast Asia (2-9).
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This article demonstrates the findings of 99mTc-HMPAO cere
bral perfusion SPECT in a case with cerebral sparganosis.
CASE REPORT
A 74-yr-old man patient presented to our hospital with seizure
and progressive weakness of the right side of his body for 1 mo.
The patient did not have a fever. Neurological examination
revealed decreased sensation and muscle power of the right side of
the body. The white blood cell count on admission was 5,900/mm3,
and the differentiation showed 70% granulocytes, 19% lympho
cytes, 4% eosinophils and 7% monocytes. EEG revealed continu
ous, focal, slow waves over the left frontotemporoparietal area.
Brain CT revealed a cystic, enhancing mass lesion at left temporal
area (Fig. 1). Brain MRI also revealed a mass lesion with
hypointensity on T l-weighted images and hyperintensity on T2-
weighted images (Fig. 1) with heterogeneous enhancement at the
left temporal area. Based on the clinical presentations, examina
tions, CT and MRI findings brain tumor was suspected.
Technetium-99m-HMPAO cerebral perfusion SPECT was ar
ranged to evaluate the regional blood flow to the intracranial mass
lesion. SPECT imaging was performed using a triple-head gamma
camera equipped with fan-beam collimatore. Acquisition was
started 20 min after an intravenous injection of 925 MBq (25 mCi)
99mTc-HMPAO in 120 projections, 3Â°apart, in a 128 X 128 matrix.
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